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Berberine is one of the main alkaloids found in the Chinese herb Huang lian (Rhizoma Coptidis), which has been reported to
have multiple pharmacological activities. This study aimed to analyze the molecular targets of berberine based on literature data
followed by a pathway analysis using the PANTHER program. PANTHER analysis of berberine targets showed that the most
classes of molecular functions include receptor binding, kinase activity, protein binding, transcription activity, DNA binding,
and kinase regulator activity. Based on the biological process classification of in vitro berberine targets, those targets related to
signal transduction, intracellular signalling cascade, cell surface receptor-linked signal transduction, cell motion, cell cycle control,
immunity system process, and protein metabolic process are most frequently involved. In addition, berberine was found to interact
with a mixture of biological pathways, such as Alzheimer’s disease-presenilin and -secretase pathways, angiogenesis, apoptosis
signalling pathway, FAS signalling pathway, Hungtington disease, inflammation mediated by chemokine and cytokine signalling
pathways, interleukin signalling pathway, and p53 pathways. We also explored the possible mechanism of action for the antidiabetic eﬀect of berberine. Further studies are warranted to elucidate the mechanisms of action of berberine using systems biology
approach.

1. Introduction
The majority of clinical drugs achieve their eﬀect by binding
to a cavity and regulating the cavity, of its protein targets
[1]. In general, drugs act on four main types of regulatory
proteins that mediate the actions of hormones, neurotransmitters, and autacoids. These four types of regulatory proteins are carriers, proteins, ion channels, and receptors [2].
Certain characteristics are expected for therapeutic targets
[3]. A potential target needs only not to be druggable but also
linked to disease, most preferably playing critical and inimitable roles in disease state. Binding sites are to have certain
structural and physiochemical properties to accommodate
high-aﬃnity site-specific binding and subsequent regulation

of protein activity by drugs. They are not significantly
involved in other important biological processes to avoid
potential side eﬀects. Useful information about these targets
may be investigated by analysing their sequence properties,
protein families, structural folds, biochemical classes, similarity proteins, gene location in the human genome, and
associated pathways [4]. This information can be potentially
useful in derivation of rule and developing predictive tools in
the search for druggable and potential targets [4].
The number of molecular targets acted on by current
drug therapy is still in dispute. In 1996, Drews and Ryser
identified a total of 483 drug targets addressed by drug
therapy [5, 6]. Approximately 45% are cell membrane receptors, 28% are enzymes, and the remaining classes comprise
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hormones (11%), ion channels (5%), nuclear receptors
(2%), and DNA (2%). About 7% of the targets are not
known biochemically. Later, Hopkins and Groom challenged
this figure and suggested that “rule-of-five” compliant drugs
acted primarily through only 120 underlying molecular
targets [3, 7]. However, the statistical analysis of disease
genes and related proteins suggested that the total number
of the estimated potential targets in the human genome
ranges from 600 to 1,500 [3]. In the meantime, another
report showed the estimated total number of distinct targets
is in the range of 1,700–3,000 [8]. Chen et al. reported
targets collected in the Therapeutic Target Database [9] is
997 distinct proteins, 1,494 distinct protein subtypes, and
41 nucleic acids, which are only targeted by at least one
marketed drug and 1,267 research targets, which are only
targeted by investigational agents that are not approved for
clinical use at present [4]. Targets for neoplasm diseases,
circulatory system diseases, infectious diseases, and nervous
system and sense organs disorders constitute the largest
number of targets [1]. An increase in target numbers is
made possible by advances in genomics, proteomics, better
molecular understanding of diseases, and increased eﬀort in
the exploration of new therapeutic targets as well as increased
knowledge of unknown or unreported targets of previous
existing drugs. An improvement in technology for target
identification and validation also contributes greatly.
Chinese herbal medicine (CHM) has always been an
integral part of traditional Chinese medicine (TCM), which
has been practiced in the east for thousands of years. Chinese
herbs are usually in the forms of dried whole plants or parts
of the plants (roots, leaves, body, etc.); sometimes shells and
even minerals are used. Chinese herbs are often used in
a compound formula, consisting of several diﬀerent herbs
hosting diﬀerent roles according to the principle of JunChen-Zuo-Shi described by the ancient Chinese. Each of
Jun, Chen, Zuo, and Shi function together to harmonise the
body, with Shi (courier) herbs are included in many formulae
to ensure that all components in the prescription are well
absorbed and to help to deliver or guide them to the target
organs [10]. On some level, the guiding function of Shi
herbs relates to modern drug delivery techniques, guiding
the drug compound to target tissues. In the modern world,
complementary medicine has gained vast popularity in the
West. There has been increased use of herbal medicine to
manage chronic diseases and promote wellbeing, in countries
such as Australia, New Zealand, USA, and Europe [11].
Reports show that 18.9% of the American population used
natural products in the precedent year [12]. This increase
in popularity is closely related to its proven eﬀectiveness in
clinical practice over the past centuries. To date, more than
11,000 species of plants are used medicinally and about 300
are commonly used [13].
Despite its widespread use, CHM is associated with high
levels of uncertainty. This is mainly due to lack of evidence,
base of eﬃcacy, targets, and safety data. During the process of
therapeutic drug development, owing to the preselection of
targets, researchers have a basic if not full understanding of
which molecular structures the drug will react with or which
biological pathway in the body it might alter. Knowledge

The Scientific World Journal
on molecular interactions and modulations of the drug is
anticipated and researched on. However, this is not the case
for CHM. There is no preselection of molecular targets in
the body but CHM has been used for thousands of years and
is proven to be eﬀective. The exact mechanism of the herbs
actions is yet to be elucidated.
The proven clinical eﬃcacy of some herbal medicines is
considered to be due to the interaction of pharmacologically
active components from the herbs with molecular targets in
the body. Similar to synthetic drugs, active compounds of
herbal medicine may bind to and undergo interactions with
molecular structures or herbal targets to produce therapeutic
or adverse eﬀects. However, there is a lack of understanding
of how CHMs exert their biological and clinical eﬀects at a
molecular level, which impedes development of CHMs and
the incorporation of CHMs into mainstream medicine in the
West.
Berberine (Figure 1, molecular formula C20 H19 NO5 and
a molecular weight of 353.36) is an isoquinoline alkaloid
found in many medicinal plants [14]. It is a major constituent of many medicinal plants of families Papaveraceae,
Berberidaceae, Fumariaceae, Menispermaceae, Ranunculaceae, Rutaceae, and Annonaceae [15]. It is present in
Hydrastis canadensis (goldenseal), Coptis chinensis (Coptis or
goldenthread), Berberis aquifolium (Oregon grape), Berberis
vulgaris (barberry), and Berberis aristata (tree turmeric).
The berberine alkaloid can be found in the roots, rhizomes,
and stem bark of the plants. Berberine is one of the main
alkaloids found in the Chinese herb Huang Lian (Rhizoma
coptidis) [16]. Huang Lian has traditionally been used to
treat diarrhoea and diabetes. In China, berberine has been
manufactured into the over-the-counter drug Huang Lian
Su Pian, also known as Coptis Extract Tablets for the
treatment of traveler’s diarrhoea [14, 17]. In recent years,
there has been a growing interest in the pharmacological
activities of berberine and many studies have been carried
out to elucidate the mechanisms of action of berberine.
This study aims to review molecular targets of berberine
based on in vitro studies. Berberine has shown to have good
hypoglycaemic eﬀects, so we also reviewed the eﬀects of
berberine in animal and human studies, with a focus on
diabetes mellitus.

2. Methods
2.1. Data Retrieval from the Literature. In vitro studies related
to berberine and its targets were searched using Pubmed
(from inception to April 2012). Search terms used were a
combination of “berberine,” “in vitro,” “human cell,” and
“mechanism.” Only studies using human cell lines were used
to extract current berberine targets. Studies using animal cell
lines or berberine derivatives or in a language other than
English were excluded. Information extracted from these
studies includes molecular targets of berberine (name and
gene symbols), cell type, eﬀects of berberine, and possible
clinical applications.
2.2. PANTHER Analysis. Using the PANTHER Classification
System, in vitro berberine targets were analysed using three
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Figure 1: Chemical structure of berberine.

approaches: molecular function, biological process, and
pathway involvement Table 2. PANTHER is a publicly
available database that relates protein sequence evolution
to evolution of protein functions and biological roles
(http://www.pantherdb.org/).

3. Results
3.1. Targets of Berberine. A total of 90 berberine targets were
identified in our literature search, as shown in Table 1.
Extensive research has been carried out to study the
eﬀects of berberine on cancer cells in vitro. This may be
related to recent discovery of anti-cancer drugs with natural
compound origin, for example, paclitaxel and topotecan.
Various human cancer cell lines were used to demonstrate the anti-cancer eﬀects of berberine in vitro. These
include cancer cell lines of the tongue, stomach, lung, colon,
liver, breast, prostate, nasopharyngeal, neurones, epidermal,
and blood [18–28]. Berberine has shown to induce cancer
cell death via several mechanisms such as regulation of
apoptosis proteins and cell cycle arrest.
Berberine treatment increased the expression of apoptotic cell death proteins, promotes cell cycle arrest, and
induces cell death in human cancer cell lines. For instance,
in human prostate epithelial cells (PWR-1E), berberineincreased expression of BCL2-associated X protein (Bax)
was observed after berberine treatment, inducing cell death
and demonstrating pro-apoptotic properties [29]. Similar
eﬀects of berberine were observed in prostate carcinoma
cells (DU145, PC-3, and LNCaP) [21, 30]. Berberine also
increased levels of Bax in promyelocytic leukemia cells [31],
gastric carcinoma cells [24], and lung cancer cells [20].
Berberine can also promote cell death by the regulation
of antiapoptotic proteins. Decreased expression of antiapoptotic Bcl-2 protein was observed in human oral squamous
cell carcinoma after berberine treatment [23]. Studies done
in other cancer cell lines such as lung cancer, gastric cancer,
and prostate cancer also showed reduced levels of Bcl-2 after

berberine treatment [20, 21, 24, 30]. Cell cycle arrest at
diﬀerent phases has also been observed in human cancer cell
lines after treatment with berberine. In giant cell carcinoma
and prostate carcinoma cells, berberine also decreased G0 /G1
phase-associated cyclins (D1 , D2 , E, Cdk2, Cdk4, and Cdk6),
inducing G0 /G1 arrest and suppressing cell proliferation [21,
25, 30, 32]. Further, in HepG2 cells, berberine acted on Bcell CLL/lymphoma 2 (BCL2), procaspase-3 and -9, and poly
(ADP-ribose) polymerase (PARP), induced cell cycle arrest at
G2 /M phase and inhibited cell proliferation [22].
Further, berberine can promote cell death via the regulation of pro- and antiapoptotic proteins. In addition to
this, berberine can also promote apoptosis via mitochondrial/caspase pathway. In cancer cell lines (tongue cancer,
oral squamous cell carcinoma and prostate epithelial) [18,
23, 29, 33], activation of caspases-3 & -9 promotes G1
cell cycle arrest in diﬀerent human cancer cell lines (lung,
stomach, and prostate) [20, 21, 24, 30, 33].
Berberine also showed anti-metastatic properties in
several cancer cell lines, acting on 72 kDa type IV collagenase
(MMP2), Cdc42 eﬀector protein 1 (CDC42EP1), and rasrelated C3 botulinum toxin substrate 1 (RAC1), transforming protein RhoA (RHOA) and urokinase-plasminogen
activator A (PLAU) [34, 35]. Further, berberine showed
antitopoisomerase I properties [36]; this observation can be
useful as topoisomerase I is responsible for DNA replication
and antitopoisomerase I compounds can be eﬀective in
cancer treatments.
In addition to its eﬀects on cancer cells, berberine also
acts on molecular targets related to insulin resistance. In freefatty-acid-induced insulin resistance muscle cells, berberine
improves insulin resistance and improves glucose uptake by
decreasing PPARγ and FAT/CD36 protein expression [37].
Another study reported increased insulin receptor (InsR)
mRNA and protein expression increases insulin sensitivity
in liver cells after berberine treatment [38]. In Caco-2 cells,
berberine inhibited alpha-glucosidase and disaccharidases
activities, leading to reduced glucose levels [39]. In Hep G2

Anticancer (leukemia, colon
cancer, brain tumour, etc.)

Decrease in N-acetyltransferase
(NAT) protein and expression of
mRNA

BCL2

Bcl-3
BAD

B-cell lymphoma 3-encoded protein

Bcl2 antagonist of cell death

HepG2 cells, oral squamous cell
carcinoma, tongue cancer SCC-4
cells, colonic carcinoma cells,
lung cancer cells, breast cancer
MCF-7 (estrogen receptor+)
cells, prostate carcinoma cells
(DU145 and PC-3, LNCaP),
activated rheumatoid arthritis
fibroblast-like synoviocytes
(RAFLSs)
Gastric carcinoma SNU-5 cells
Human oral squamous cell
carcinoma

[77]

Anticancer and
anti-inflammatory agent

Jurkat cells

BIRC5

Downregulation of Bcl-3
Increased expression of
proapoptotic BAD protein

Bcl-2 Downregulation

Suppresses expression of survivin

[77]

Anticancer

Suppresses expression of
antiapoptosis factor IAP2

Jurkat cells

BIRC3

Antitumour

Gastric cancer

[23]

[24]

Cell apoptosis, cancer, and ER
[19–23, 30, 34, 82, 83]
antagonist adjuvant therapy

[19, 77]

Anticancer

Suppresses expression of
antiapoptosis factor IAP1

Jurkat cells, colonic carcinoma
cells (SW620)

BIRC2

[81]

[78–80]

[19–21, 30, 76, 77]

[75]

[74]

Decrease in ABCG2 expression

Breast cancer

Cell apoptosis, anticancer, and
anti-inflammatory

Alzheimer disease

JNK/p38 pathway and induction of
ROS production. Decreased
expression

Reduces amyloid-β peptide (Aβ)
levels via modulation of APP

Apoptosis

[73]

[18, 69–72]

References

MCF-7 breast cancer cells

Colonic carcinoma cells, HepG2
cells/A549 cells, prostate
carcinoma cells (DU145 and
PC-3, LNCaP), Jurkat cells
Leukemia HL-60 cells, colon
tumour cells, brain tumour cells
(G95/VGH and GBM 8401)

Neuroglioma H4 cells

HepG2 hepatoma cells

Antihyperlipidemic

Antimetastatic

Downregulation of MMP2 mRNA
and protein expression, reduced
MMP-2 levels
Phosphorylation
Reduced secretion of alpha
fetoprotein

Possible clinical applications

Eﬀects

ABCG2

NAT

B-cell CLL/lymphoma 2

ATP-binding cassette subfamily G
member 2
Baculoviral IAP repeat-containing
protein 2 (antiapoptosis factor
c-IPA-1)
Baculoviral IAP repeat-containing
protein 3
Baculoviral IAP repeat-containing
protein 5 (Survivin)

Arylamine N-acetyltransferase 1

BCL2L1

APP

Amyloid-β (A4) precursor protein
(peptidase nexin-II, Alzheimer
disease)

Bcl-X

AFP

Target gene symbol Cells
HUVECs, tongue cancer SCC-4
cells, gastric carcinoma SNU-5
MMP2
cells, lung cancer A549 cells, and
U-87 glioma cells
ACACA
HepG2 hepatoma cells

α-Fetoprotein

Acetyl-Coenzyme A carboxylase-α

72 kDa type IV collagenase

Target names

Table 1: Potential targets of berberine.
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Activated caspase 8

Anticancer

[18, 19, 23, 76]

[18–21, 23–
25, 30, 33, 76, 83, 86–
89]

[77]

Anticancer and
anti-inflammatory

Suppresses expression of cFLIP

Activation of caspase-3, G2/M phase
Anticancer
arrest

[85]

Cervical cancer

Induced expression of GADD153

[19, 76]

[18, 20, 21, 24, 29, 30,
83, 84]

Induction of apoptosis

Cell apoptosis, gastric cancer

Upregulation of Bax, increased
expression. G2/M phase arrest

References

JNK/p38 pathway and induction of
ROS production

Possible clinical applications

Eﬀects

Table 1: Continued.

Target gene symbol Cells
Gastric carcinoma SNU-5 cells,
prostate carcinoma cells (DU145,
PC-3, LNCaP and PWR-1E),
leukemia HL-60, tongue cancer
BAX
SCC-4 cells, lung cancer cells,
activated rheumatoid arthritis
fibroblast-like synoviocytes
(RAFLSs)
Colonic carcinoma cells/HepG2
BID
cells

BH3-interacting domain death
agonist p11
C/EBP homologous protein (CHOP)
or growth arrest- and DNA
Cervical cancer
GADD153/DDIT3
damage-inducible gene 153
Ca Ski cells
(GADD153) or DNA
damage-inducible transcript 3
CASP8 and FADD-like apoptosis
CFLAR/cFLIP
Jurkat cells
regulator subunit p12
Tongue cancer SCC-4 cells,
neuroblastoma (SK-N-SH),
glioblastoma T98G cells, gastric
carcinoma SNU-5 cells, HL-60
cells, prostate carcinoma cells
(DU145, PWR-1E, PC-3 and
LNCaP), colonic carcinoma cells,
Caspase 3
CASP3
hepatoma cells, oral squamous
cell carcinoma, promonocytic
U937 cells, lung cancer A549,
H1301 cells, activated
rheumatoid arthritis
fibroblast-like synoviocytes
(RAFLSs), BIU-87 and T24
bladder cancer cells
Tongue cancer SCC-4 cells,
colonic carcinoma cells,
Caspase 8
CASP8
hepatoma cells, oral squamous
cell carcinoma

BCL2-associated X protein

Target names

The Scientific World Journal
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CCNE1

CDK2

Cyclin-dependent kinase 2

Decrease in Cdk2

Decrease in cyclin E

Inactivation of Cdc2 (CDK1) or
decreased protein expression

HL-60 cell, gastric carcinoma
SNU-5 cells
Neuroblastoma (SK-N-SK),
glioblastoma T98G cells,
activated rheumatoid arthritis
fibroblast-like synoviocytes
(RAFLSs)
Neuroblastoma (SK-N-SK),
glioblastoma T98G cells, prostate
carcinoma cells (DU145 and
PC-3, LNCaP), activated
rheumatoid arthritis
fibroblast-like synoviocytes
(RAFLSs)

CDK1/CDC2

Induces ATF3 expression

Colorectal cancer cells

ATF3

Inhibits CCL2 (MCP-1) expression

Cell apoptosis, anticancer

Anticancer

Antiproliferative and
proapoptotic

Colorectal cancer

Anti-inflammatory

Increased expression of p53 protein,
Anticancer (gastric cancer,
cell cycle arrest at G1G2/M phase
osteosarcoma)
arrest

Retinal pigment epithelial cell
line

Gastric carcinoma SNU-5 cells,
osteosarcoma

CCL2

TP53

Cell apoptosis, cancer

Cancer metastasis inhibition

Suppression of Rho GTPases
activation (Cdc42)

Decrease in Cdk6

Cell apoptosis, anticancer

Possible clinical applications

Activation of caspase 9

Eﬀects

Table 1: Continued.

Target gene symbol Cells
Tongue cancer SCC-4 cells,
glioblastoma T98G, oral
squamous carcinoma,
promonocytic U937 cells,
prostate carcinoma cells (DU145
CASP9
and PC-3, LNCaP), activated
rheumatoid arthritis
fibroblast-like synoviocytes
(RAFLSs), BIU-87 and T24
bladder cancer cells
Nasopharyngeal carcinoma
CDC42EP1
(HONE1) cells
Prostate carcinoma cells (DU145
and PC-3, LNCaP), activated
CDK6
rheumatoid arthritis
fibroblast-like synoviocytes
(RAFLSs)

Cyclin E1

Chemokine (C-C motif) ligand 2
(monocyte chemotactic protein-1)
Cyclic AMP-dependent transcription
factor ATF-3
Cyclin-dependant kinase 1/cell
division control protein 2 homolog

Cellular tumor antigen p53

Cell division protein kinase 6

Cdc42 eﬀector protein 1

Caspase 9

Target names

[21, 25, 30, 83, 90]

[25, 83, 90]

[24, 95]

[94]

[93]

[24, 92]

[21, 30, 83]

[91]

[18, 21, 23, 30, 33, 83,
86, 87, 89, 90]

References
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EGFR
EZR

Epidermal growth factor receptor

Ezrin

CCND1

Human peripheral lymphocytes
Brest cancer MCF-7 (estrogen
receptor+) cells
Nasopharyngeal carcinoma 5–8F
cells
Giant cell carcinoma cell line,
HL-60 cell, prostate carcinoma
cells (DU145 and PC-3, LNCaP),
Jurkat cells, neuroblastoma
(SK-N-SK), activated
rheumatoid arthritis
fibroblast-like synoviocytes
(RAFLSs)

CD69

G1/S-specific cyclin-D1

Recombinant DPP4

Caco-2 cells, patients

DPP4

CYP3A4

Dipeptidyl-peptidase 4 (CD26,
adenosine deaminase complexing
protein 2)
Early activation antigen CD69

CYP3A4

Breast cancer, ER antagonist
adjuvant therapy

Cell apoptosis, cancer

Anticancer
Drug interactions
Drug interactions

Increased expression of p21

Increased expression of Cdki
proteins

Release of cytochrome c-1
Inhibition of CYP2C9
Inhibition of CYP2D6
CYP3A4 Downregulation and
inhibition

Inhibits expression of cyclin D1

Ezrin inhibition

EGFRdownregulated

Reduced expression of CD69

Inhibition of DPP4

Cell apoptosis, anticancer

Decrease in Cdk4

Antiproliferative and
proapoptotic, anticancer,
anti-inflammatory

Anticancer

Immunosuppressive agent
Breast cancer, ER antagonist
adjuvant therapy

—

Drug interactions

Possible clinical applications

Eﬀects

Table 1: Continued.

Target gene symbol Cells
Neuroblastoma (SK-N-SK),
glioblastoma T98G cells, prostate
carcinoma cells (DU145 and
Cyclin-dependent kinase 4
CDK4
PC-3, LNCaP), activated
rheumatoid arthritis
fibroblast-like synoviocytes
(RAFLSs)
Brest cancer MCF-7 (estrogen
receptor+) cells, epidermoid
Cyclin-dependent kinase inhibitor 1
carcinoma A431 cells, activated
CDKN1A
(p21)
rheumatoid arthritis
fibroblast-like synoviocytes
(RAFLSs)
Epidermoid carcinoma A431
Cyclin-dependent kinase inhibitor
cells, activated rheumatoid
CDKN1B
1B (P27/KIP1)
arthritis fibroblast-like
synoviocytes (RAFLSs)
Tongue cancer SCC-4 cells,
colonic carcinoma cells,
Cytochrome c-1
CYC1
promyelocytic leukemia HL-60
cells
CYP2C9
CYP2C9
Recombinant CYP
CYP2D6
CYP2D6
Recombinant CYP

Target names

[21, 25, 30, 32, 77, 83,
95]

[26]

[82]

[100]

[99]

[97, 98]

[96]
[96]

[18, 19, 84, 86]

[21, 30, 83]

[21, 30, 82, 83]

[21, 25, 30, 83, 90]

References
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Mitogen-activated protein kinase 3

Matrix metalloproteinase-16
ERK1/MAPK3

MMP16

MMP9

MMP1

LDLR

IL1B
IL2RA/CD25
IL6

IL8

Interleukin 8

CHUK(IKK)

MCL1

HIF1A

GDF15

IFNB1

Interleukin-1β
Interleukin-2 receptor α-chain
Interleukin-6
Low-density lipoprotein receptor
(familial hypercholesterolemia)
Matrix metallopeptidase 1 (27 kDa
interstitial collagenase)
Matrix metallopeptidase 9
(gelatinase B, 92 kDa gelatinase,
92 kDa type IV collagenase)

Table 1: Continued.

Induces IL-1B productions
Reduced expression of CD25
Reduces and IL-6 expression
Increased mRNA and protein
expression

Inhibits IL-8 expression

IFN-beta upregulated

Inhibition of IκB kinase (IKK)

Suppresses expression of MMP-16

ERK1 protein expression inhibition Antiatherosclerotic eﬀects

Jurkat cells
Peripheral blood monocytes
(PBMC)

Anticancer and
anti-inflammatory agent

Anticancer

Antiskin ageing agent,
anticancer

Hyperlipidemia

Pulmonary inflammation
Immunosuppressive agent
Antiskin ageing agent

Anti-inflammatory

Anticancer and
anti-inflammatory agent
Breast cancer, ER antagonist
adjuvant therapy

Induced apoptosis

Tumour angiogenesis

Prevention and reduction of HIF-1
alpha expression
Inhibition of Mcl-1 expression

Colorectal cancer

Antidiabetic agent

Cell apoptosis, anticancer

Cell apoptosis, cancer

Cell apoptosis, cancer

Possible clinical applications

Induces NAG-1 expression

Dermal fibroblasts, U-87 glioma
MMP-1 expression decreased
cells
Tongue cancer SCC-4 cells,
keratinocytes, gastric carcinoma Inhibition
SNU-5

HepG2 cells

Brest cancer MCF-7 (estrogen
receptor+) cells
Retinal pigment epithelial cell
line
Fibroblasts (HFL1)
Human peripheral lymphocytes
Keratinocytes

Jurkat cells

Oral cancer cells

HUVECs, HepG2 cells

Colorectal cancer cells

Target gene symbol Cells
Eﬀects
Prostate carcinoma cells (DU145
and PC-3, LNCaP), activated
CCND2
Decrease in cyclin D2
rheumatoid arthritis
fibroblast-like synoviocytes
(RAFLSs)
Prostate carcinoma cells (DU145
and PC-3, LNCaP), activated
CCNE1
rheumatoid arthritis
Decrease in cyclin E
fibroblast-like synoviocytes
(RAFLSs)
Decreased cyclin B, G2/M phase
CCNB1
Gastric carcinoma SNU-5 cells
arrest
Enhanced glucagon-like peptide
GCG
NCI-H716 cells
(GLP)-1

Interferon-γ

Induced myeloid leukemia cell
diﬀerentiation protein Mcl-1
Inhibitor of NF-κB kinase subunit
alpha (IκB kinase)

Hypoxia-inducible factor 1α

Glucagon-like peptide
(GCG/GLP-1/GLP-2)
Growth/diﬀerentiation factor 15
(NAG-1)

G2/mitotic-specific cyclin-B1

G1/S-specific cyclin-E1

G1/S-specific cyclin-D2

Target names

[110]

[77]

[34, 70, 105]

[70, 109]

[106–108]

[104]
[100]
[105]

[93]

[82]

[77]

[103]

[101, 102]

[94]

[42]

[24]

[21, 30, 83]

[21, 30, 83]

References
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PARP

KCNH2/HERG1

Potassium voltage-gated channel
subfamily H member 2

CD36/FAT

Leukemic stem cells (LSCs)

Free-fatty-acid-induced insulin
resistance muscle cells-L6
myotubes, 3T3-L1 preadipocytes
Free-fatty-acid-induced insulin
resistance muscle cells-L6
myotubes
HepG2 cells/hepatoma cells,
colonic carcinoma cells, prostate
cancer cells (PC-3), prostate
carcinoma cells (DU145 and
PC-3, LNCaP), activated
rheumatoid arthritis
fibroblast-like synoviocytes
(RAFLSs)

Leukemia HL-60 cells

NPM1

PPARG

HepG2 cells

Jurkat cells, osteoblastic cells,
HepG2 cells

Lung epithelial cells (A-549)

U-87 glioma cells

Hepatoma
HepG2 cells

Tumour cell lines

HL-60 cell

Peripheral blood monocytes
(PBMC)

NR3C1

Poly (ADP-ribose) polymerase
family, member 1

Platelet glycoprotein 4

Peroxisome proliferator-activated
receptor-γ

Nuclear receptor subfamily 3, group
C, member 1 (glucocorticoid
receptor)
Nucleophosmin (nucleolar
phosphoprotein B23) and
telomerase

NFKB1

MYC

Myc proto-oncogene protein

Nuclear factor NF-κB p50 subunit
(NF-κB)

ABCB1

Multidrug resistance protein 1 (P-gp,
P-gp-170)

NFKBIA

CDC25A

M-phase inducer phosphatase 1

NF-κB inhibitor-α

MAPK8

Possible clinical applications

Reduced retention of
chemotherapeutic agents
Malignant glioma and cancer
development

MDR activity reversal

Antiproliferative and
proapoptotic

Antiatherosclerotic eﬀects

Cell growth arrest

Inhibits HERG1 K (+) channels of
leukemic cells

Cleavage of poly (ADP-ribose)
polymerase. Activation of PARP

Decreased expression

Decreased expression

Inhibits AML cell migration

Cell apoptosis, Anticancer

Antidiabetic

Antidiabetic

Downregulation of
nucleophosmin/B23 and telomerase Cancer
activity

Reduced GR levels

Inhibition of κB-α phosphorylation
Pulmonary inflammation
and degradation
Anticancer and
Inhibit NF-κB production and
anti-inflammatory agent,
suppress NF-κB
alcohol liver disease, osteoclast
formation

Myc level decreased

Jun N-terminal kinase (JNK)
protein expression inhibited at high
levels of BBR
Phosphorylation and degradation of
Cdc25A
Significant inhibited P-gp multidrug
resistance (MDR) activity
Upregulated multidrug resistance
transporter (P-gp-170) expression

ERK2 protein expression inhibition Antiatherosclerotic eﬀects

Eﬀects

Table 1: Continued.

Target gene symbol Cells
Peripheral blood monocytes
ERK2/MAPK4
(PBMC)

Mitogen-activated protein kinase 8
(JNK)

Mitogen-activated protein kinase 4

Target names

[35]

[19, 21, 22, 30, 76, 83,
87]

[37]

[37, 117]

[116]

[74]

[77, 113–115]

[104]

[71]

[112]

[111]

[95]

[19, 110]

[110]

References

The Scientific World Journal
9

Top1

AP-1

RHOA
TNFA
PLAU
VEGFA
Wee1

Transcription factor AP-1

Transforming protein RhoA

Tumor necrosis factor-α

Urokinase-plasminogen activator

Vascular endothelial growth factor A

Wee1-like protein kinase

CXCL12
SI

SDF-1-α (3–67) (SDF-1)
Sucrase-isomaltase (α-glucosidase)

Topoisomerase (DNA) I

RUNX2

ROCK1/RHO

ERBB2/HER2

RAC1

ROS1

PTGS2/COX2

Gastric carcinoma SNU-5 cells

Acute myeloid leukemia (AML)
Caco-2 cells
Recombinant human
topoisomerase I
Hepatoma cells, MDA-MB-231
breast cancer cells, giant cell
carcinoma cell line, colon cancer
cells, U-87 glioma cells, HeLa
cells
Nasopharyngeal carcinoma
(HONE1) cells
Macrophages, fibroblasts (HFL1)
Lung cancer A549 cells, tongue
cancer SCC-4 cells
HUVECs

Osteoblast cells

Nasopharyngeal carcinoma
(HONE1) cells
Brest cancer MCF-7 (estrogen
receptor+) cells
Nasopharyngeal carcinoma 5–8F
cells

HUVECs

Gastric cancer

Tumour angiogenesis

Antimetastatic, Anticancer

Anti-inflammatory

Cancer metastasis inhibition

Antitumor activity, Anticancer

Inhibition of AP-1 activity, AP-1
DNA suppression
Suppression of Rho GTPases
activation (RhoA)
Inhibition of TNF-α
Reduced urokinase-plasminogen
activator (u-PA)
Prevention of VEGF expression
Increased expression of
Wee1protein, G2/M phase arrest

Anticancer

Top1 inhibition

[24]

[102]

[34, 72]

[104, 125]

[91]

[27, 32, 71, 115, 118,
122–124]

[121]

[35]
[39]

[120]

[91]

[82]

Breast cancer, ER antagonist
adjuvant therapy
Anticancer

[91]

[19, 119]

Cancer metastasis inhibition

Protects LDL oxidation and
prevents ox-LDL-induced
cellular dysfunction

Osteoblast diﬀerentiation and
Promotes transcriptional activity of
bone formation in
Runx2
osteoporosis
Reduces SDF-1 chemokine
Inhibits AML cell migration
Inhibit alpha-glucosidase
Antihyperglycaemic

Suppression of Rho kinase activity

HER2 downregulated

Suppression of Rho GTPases
activation (Rac1)

Inhibition of ROS generation

Decrease of Cox-2 mRNA and
protein expression

Peripheral blood monocytes
(PBMC), oral cancer cell lines
OC2 and KB cells, breast cancer
MCF-7 (estrogen receptor+)
cells, Jurkat cells, colon cancer
cells

[101, 107]

[101]

References

Antiatherosclerotic eﬀects,
anti-inflammatory, anticancer, [27, 77, 82, 103, 110,
breast cancer ER antagonist
118]
adjuvant therapy, Anticancer

Hyperlipidemia

Suppression of PCSK9 mRNA and
protein levels

HepG2 cells

PCSK9

Possible clinical applications
Hyperlipidemia

Eﬀects

Table 1: Continued.
Reduction of SREBP2

HepG2 cells

SREBP2

Target gene symbol Cells

Runt-related transcription factor 2

Rho-associated protein kinase 1

Ras-related C3 botulinum toxin
substrate 1
Receptor tyrosine-protein kinase
erbB-2

Proto-oncogene tyrosine-protein
kinase ROS

Prostaglandin G/H synthase 2

Target names
Processed sterol regulatory
element-binding protein 2
Proprotein convertase
subtilisin/kexin type 9
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AFP

AP-1

APP

ATF3

BAD

BAX

Transcription factor AP-1

Amyloid-β (A4) precursor
protein (peptidase nexin-II,
Alzheimer disease)

Cyclic AMP-dependent
transcription factor ATF-3

Bcl2 antagonist of cell death

BCL2-associated X protein

ACACA

Acetyl-coenzyme A
carboxylase-α

α-Fetoprotein

ABCG2

Other signaling molecule

N/A

DNA binding, transcription factor activity

Other signaling molecules

DNA binding, transcription factor activity

Other transfer/carrier protein

Other ligase

ATPase activity, coupled to transmembrane
movement of substances, transmembrane
transporter activity, anion channel activity

Target gene symbol PANTHER molecular function
ATPase activity, coupled to transmembrane
ABCB1
movement of substances, transmembrane
transporter activity

ATP-binding cassette sub-family
G member 2

Multidrug resistance protein 1
(Pgp, Pgp-170)

Target names

p53 pathway, apoptosis signaling
pathway, Huntington disease

N/A

Induction of apoptosis, gametogenesis,
hematopoiesis, cell cycle control, cell
proliferation and diﬀerentiation, tumor
suppressor

Apoptosis signaling pathway

Toll receptor signaling pathway,
inflammation mediated by
chemokine and cytokine signaling
pathway, apoptosis signaling
pathway, oxidative stress response,
angiogenesis, TGF-beta signaling
pathway, T-cell activation, B-cell
activation, Ras Pathway, FAS
signaling pathway, PDGF signaling
pathway
Alzheimer disease-amyloid secretase
pathway, Alzheimer
disease-presenilin pathway, blood
coagulation, Alzheimer
disease-presenilin pathway,
Alzheimer disease-amyloid secretase
pathway

N/A

N/A

N/A

ATP-binding cassette (ABC)
transporter

Pathway categories

PDGF signaling pathway, apoptosis
signaling pathway, angiogenesis, PI3
kinase pathway, VEGF signaling
pathway, interleukin signaling
pathway

Transcription factor activity, immune system
process, neurological system process,
induction of apoptosis, nucleobase,
nucleoside, nucleotide, and nucleic acid
metabolic process

Other signal transduction, cell
communication, other intracellular protein
traﬃc

Cell cycle, intracellular signaling cascade,
nucleobase, nucleoside, nucleotide, and
nucleic acid, metabolic process, cell cycle,
signal transduction

Biological process
Immune system process, extracellular
transport, carbohydrate metabolic process,
response to toxin
Immune system process, anion transport,
lipid transport, oxygen and reactive oxygen
species, metabolic process, lipid metabolic
process, response to stress
Gluconeogenesis, monosaccharide
metabolism, fatty acid biosynthesis,
coenzyme metabolism
Transport, mesoderm development,
oncogenesis

Table 2: Berberine’s target classification based on PANTHER.
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CASP8

CASP9

CCL2
CCNB1
CCND1
CCND2
CCNE1

Caspase 8, apoptosis-related
cysteine peptidase

Caspase 9, apoptosis-related
cysteine peptidase

Chemokine (C-C motif) ligand
2 (monocyte chemotactic
protein-1)

G2/mitotic-specific cyclin-B1

G1/S-specific cyclin-D1

G1/S-specific cyclin-D2

Cyclin E1

Kinase activator

Protein binding, kinase activator activity,
kinase regulator activity
Protein binding, kinase activator activity,
kinase regulator activity
Protein binding, kinase activator activity,
kinase regulator activity

Nonreceptor serine/threonine, protein
kinase

Cysteine protease

Cysteine protease

Cysteine protease

N/A

BIRC5

CASP3

N/A

BIRC3

Caspase 3, apoptosis-related
cysteine peptidase

N/A

BIRC2

N/A
N/A

Bcl-3

B-cell lymphoma 3-encoded
protein

Receptor binding

Other signaling molecule

BID

BCL2L1

Apoptosis regulator Bcl-X

BH3-interacting domain death
agonist p11
Baculoviral IAP
repeat-containing protein 2
(anti-apoptosis factor c-IPA-1)
Baculoviral IAP
repeat-containing protein 3
Baculoviral IAP
repeat-containing protein 5
(Survivin)

BCL2

PI3 kinase pathway, cell cycle
p53 pathway, cell cycle, Parkinson
disease, p53 pathway feedback loops
2
Cell cycle control, mitosis, cell proliferation
and diﬀerentiation

PI3 kinase pathway, cell cycle, Wnt
signaling pathway

Cell cycle, p53 pathway

N/A

Huntington disease, FAS signaling
pathway, apoptosis signaling
pathway
Apoptosis signaling pathway, FAS
signaling pathway, Huntington
disease
Angiogenesis, apoptosis signaling
pathway, FAS signaling pathway,
VEGF signaling pathway, PI3 kinase
pathway

Angiogenesis

Apoptosis signaling pathway

Apoptosis signaling pathway

Inflammation mediated by
chemokine and cytokine signaling
pathway
Apoptosis signaling pathway, FAS
signaling pathway

Apoptosis signaling pathway

Pathway categories
Oxidative stress response, apoptosis
signaling pathway

Spermatogenesis, mitosis

Spermatogenesis, mitosis

Mitosis

Protein phosphorylation, cell cycle control,
mitosis

Proteolysis, apoptosis

Proteolysis, apoptosis

Proteolysis, apoptosis

N/A

N/A

N/A

N/A

Nucleobase, nucleoside, nucleotide, and
nucleic acid metabolic process

Gamete generation, induction of apoptosis,
negative regulation of apoptosis, cell cycle,
mesoderm development, hemopoiesis

Inhibition of apoptosis, oncogenesis

Biological process

Table 2: Continued.

Target gene symbol PANTHER molecular function

B-cell CLL/lymphoma 2

Target names
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Inhibitor of NF-κB kinase
subunit alpha (IκB kinase)

Cyclin-dependent kinase
inhibitor 1B (P27/KIP1)
CASP8-and FADD-like
apoptosis regulator subunit p12

CHUK(IKK)

CFLAR/cFLIP

CDKN1B

CDKN1A

CDK6

Cell division protein kinase 6

Cyclin-dependent kinase
inhibitor 1 (p21)

CDK4

CDK1/CDC2

Cyclin dependant kinase 1/cell
division control protein 2
homolog

Cyclin-dependent kinase 4

CDC42EP1

Cdc42 eﬀector protein 1

CDK2

CDC25A

M-phase inducer phosphatase 1

Cyclin-dependent kinase 2

CD69

CD36/FAT

Platelet glycoprotein 4

Early activation antigen CD69

IL2RA/CD25

CCNE1

Mitosis

Biological process

Kinase activity

Protein binding, kinase inhibitor activity,
kinase regulator activity
Peptidase activity, protein binding,
peptidase inhibitor activity

Protein binding, kinase inhibitor activity,
kinase regulator activity

Immune response, intracellular signaling
cascade, protein metabolic process, signal
transduction, response to stimulus

Apoptosis, protein metabolic process

Cell cycle

Cell cycle

Immune system process, cell surface
receptor-linked signal transduction,
Cytokine receptor activity
intracellular signaling cascade, cell-cell
signalling, signal transduction, cell-cell
signalling, cellular defense response
Macrophage activation, lipid transport,
apoptosis, signal transduction, cell adhesion,
Receptor activity
lipid metabolic process, signal transduction,
cell adhesion, cellular component,
morphogenesis
B-cell-mediated immunity, natural killer cell
Receptor activity, receptor binding
activation, cellular defense response
Phosphatase activity cell cycle, phosphate
Hydrolase activity, acting on ester bonds,
metabolic process, protein metabolic process,
phosphatase activity
cell cycle
N/A
N/A
Immune system process, mitosis, intracellular
signaling cascade, protein metabolic process,
Kinase activity
cell motion, mitosis, signal transduction,
response to stress
Protein phosphorylation, cell cycle control,
Nonreceptor serine/threonine protein kinase
mitosis
Protein phosphorylation, cell cycle control,
Nonreceptor serine/threonine protein kinase
mitosis
Immune system process, mitosis, intracellular
signaling cascade, protein metabolic process,
Kinase activity
cell motion, mitosis, signal transduction,
response to stress

Protein binding, kinase activator activity,
kinase regulator activity

Target gene symbol PANTHER molecular function

Interleukin-2 receptor alpha
chain

G1/S-specific cyclin-E1

Target names

Table 2: Continued.

Apoptosis signaling pathway, FAS
signaling pathway
Interleukin signaling pathway,
apoptosis signaling pathway, T-cell
activation, toll receptor signaling
pathway, B-cell activation

Interleukin signaling pathway

Interleukin signaling pathway, p53
pathway feedback loops 2, p53
pathway

N/A

N/A

p53 pathway, p53 pathway feedback
loops 2

p53 pathway

N/A

p53 pathway

Membrane-bound signaling
molecule

N/A

Interleukin signaling pathway

Pathway categories
p53 pathway, cell cycle, Parkinson
disease, p53 pathway feedback loops
2
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Receptor tyrosine-protein kinase
erbB-2

Epidermal growth factor
receptor

ERBB2/HER2

EGFR

DPP4

CYP3A4

CYP2D6

Cytochrome P450, family 2,
subfamily D, polypeptide 6

Cytochrome P450, family 3,
subfamily A, polypeptide 4
Dipeptidyl-peptidase 4 (CD26,
adenosine deaminase
complexing protein 2)

CYP2C9

CYC1

CXCL12

Kinase activity, transmembrane receptor
protein tyrosine kinase activity,
transmembrane receptor protein kinase
activity, receptor binding

Kinase activity, transmembrane receptor
protein tyrosine kinase activity,
transmembrane receptor protein kinase
activity, receptor binding

Serine protease

Oxygenase

Oxygenase

Oxygenase

Reductase

N/A

Target gene symbol PANTHER molecular function

Cytochrome P450, family 2,
subfamily C, polypeptide 9

Cytochrome c-1

SDF-1-α (3–67) (SDF-1)

Target names

Fatty acid metabolism, steroid metabolism,
electron transport
Other lipid, fatty acid and steroid
metabolism, steroid metabolism, electron
transport
Steroid hormone metabolism, electron
transport
Proteolysis, cell surface receptor mediated
signal transduction, T-cell-mediated
immunity
Female gamete generation, immune system
process, negative regulation of apoptosis, cell
cycle, cell surface receptor-linked signal
transduction, intracellular signaling cascade,
cell-cell signalling, cell-cell adhesion, protein
metabolic process, cell motion, cell
cyclesignal transduction, cell-cell signalling,
dorsal/ventral axis specification, ectoderm
development, mesoderm development,
embryonic development, nervous system
development
Female gamete generation, immune system
process, negative regulation of apoptosis, cell
cycle, cell surface receptor linked signal
transduction, intracellular signaling cascade,
cell-cell signalling, cell-cell adhesion, protein
metabolic process, cell motion, cell
cyclesignal transduction, cell-cell signalling,
dorsal/ventral axis specification, ectoderm
development, mesoderm development,
embryonic development, nervous system
development

Oxidative phosphorylation

N/A

Biological process

Table 2: Continued.

EGF receptor signaling pathway,
cadherin signaling pathway

EGF receptor signaling pathway,
cadherin signaling pathway

N/A

N/A

Vitamin D metabolism and pathway

N/A

Pathway categories
Axon guidance-mediated by
Slit/Robo
FAS signaling pathway, ATP
synthesis, Huntington disease
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Glucagon-like peptide
(GCG/GLP-1/GLP-2)
GCG

GADD153/DDIT3

EZR

ERK2/MAPK4

Mitogen-activated protein
kinase 4

Ezrin
C/EBP homologous protein
(CHOP) or growth arrest- and
DNA damage-inducible gene
153 (GADD153) or DNA
damage-inducible transcript 3

ERK1/MAPK3

Receptor binding

N/A

Structural constituent of cytoskeleton

Kinase activity

Kinase activity

Target gene symbol PANTHER molecular function

Mitogen-activated protein
kinase 3

Target names

Oxidative stress response

Peptide hormone

N/A

Signal transduction, cell-cell signalling,
carbohydrate metabolic process, lipid
metabolic process, signal transduction,
cell-cell signalling, cellular glucose
homeostasis

Pathway categories
Apoptosis signaling pathway,
Alzheimer disease-amyloid secretase
pathway, B-cell activation, Ras
pathway, interleukin signaling
pathway, angiogenesis, T-cell
activation, toll receptor signaling
Immune system process, mitosis, cell surface
pathway, insulin/IGF
receptor linked signal transduction,
pathway-mitogen activated protein
intracellular signaling cascade, carbohydrate
kinase kinase/MAP kinase cascade,
metabolic process, protein metabolic process,
FGF signaling pathway, Parkinson
cell motion, signal transduction, segment
disease, PDGF signaling pathway,
specification, ectoderm development,
inflammation mediated by
mesoderm development, embryonic
chemokine and cytokine signaling
development, nervous system development,
pathway, VEGF signaling pathway,
response to stress
interferon-gamma signaling
pathway, endothelin signaling
pathway, angiogenesis, TGF-beta
signaling pathway, integrin
signalling pathway, EGF receptor
signaling pathway
Immune system process, mitosis, cell surface
receptor linked signal transduction,
intracellular signaling cascade, carbohydrate Alzheimer disease-amyloid secretase
metabolic process, protein metabolic process, pathway, interleukin signaling
cell motion, mitosis, signal transduction,
pathway, angiogenesis, VEGF
segment specification, ectoderm
signaling pathway, integrin
development, mesoderm development,
signalling pathway
embryonic development, nervous system
development, response to stress
Cellular component, morphogenesis
N/A

Biological process

Table 2: Continued.
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IFNB1

IL1B

IL6

IL8

Interferon-β

Interleukin-1β

Interleukin-6

Interleukin 8

Low-density lipoprotein
receptor (familial
hypercholesterolemia)
LDLR

KCNH2/HERG1

HIF1A

Hypoxia-inducible factor 1α

Potassium voltage-gated channel
subfamily H member 2

GDF15

Biological process
Female gamete generation, cell surface
receptor linked signal transduction, signal
transduction, ectoderm development,
mesoderm development, skeletal system
development, heart development, muscle
organ development
Nucleobase, nucleoside, nucleotide, and
nucleic acid metabolic process, ectoderm
development, nervous system development
Response to interferon-gamma, induction of
apoptosis, negative regulation of apoptosis,
cell surface receptor linked signal
transduction, intracellular signaling cascade,
cell-cell signalling, signal transduction,
cell-cell signalling, cellular defense response
Immune response, macrophage activation,
cell surface receptor linked signal
transduction, cell-cell signalling, signal
transduction, cell-cell signalling, response to
stimulus
Immune system process, negative regulation
of apoptosis, cell surface receptor linked
signal transduction, intracellular signaling
cascade, cell-cell signalling signal
transduction, cell-cell signaling
Cytokine- and chemokine-mediated signaling
pathways, calcium-mediated signalling,
NF-kappaB cascade, ligand-mediated
signalling, T-cell-mediated immunity,
macrophage-mediated immunity,
granulocyte-mediated immunity,
angiogenesis, cell proliferation and
diﬀerentiation, cell motility

Other receptor

Oogenesis

Receptor activity, cation transmembrane
transporter activity, voltage-gated potassium
Cation transport, signal transduction
channel activity, cation channel activity,
cyclic nucleotide-gated ion channel activity

Chemokine

Receptor binding

Receptor binding

Receptor binding

DNA binding, transcription factor activity

Receptor binding

Target gene symbol PANTHER molecular function

Growth/diﬀerentiation factor 15
(NAG-1)

Target names

Table 2: Continued.

Alzheimer disease-presenilin
pathway

Ligand-gated ion channel

Inflammation mediated by
chemokine and cytokine signaling
pathway, interleukin signaling
pathway

Inflammation mediated by
chemokine and cytokine signaling
pathway, interleukin signaling
pathway

Inflammation mediated by
chemokine and cytokine signaling
pathway

Toll receptor signaling pathway

Hypoxia response via HIF
activation, VEGF signaling pathway,
angiogenesis

TGF-beta signaling pathway

Pathway categories
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MAPK8

MCL1

MMP1

MMP16
MMP2
MMP9

MYC

NAT

Induced myeloid leukemia cell
diﬀerentiation protein Mcl-1

Matrix metallopeptidase 1
(27 kDa interstitial collagenase)

Matrix metalloproteinase-16

72 kDa type IV collagenase

Matrix metallopeptidase 9
(gelatinase B, 92 kDa gelatinase,
92 kDa type IV collagenase)

Myc proto-oncogene protein

Arylamine N-acetyltransferase 1

Acyltransferase activity

DNA binding, transcription factor activity

Metalloprotease, other extracellular matrix

Metalloprotease, other extracellular matrix

Peptidase activity

Peptidase activity

Receptor binding

Kinase activity

Pathway categories
Alzheimer disease-amyloid secretase
pathway, Ras pathway, EGF receptor
signaling pathway, Parkinson
Immune system process, mitosis, cell surface
disease, angiogenesis, FGF signaling
receptor linked signal transduction,
pathway, FAS signaling pathway, toll
intracellular signaling cascade, carbohydrate
receptor signaling pathway,
metabolic process, protein metabolic process,
TGF-beta signaling pathway, PDGF
cell motion, mitosis, signal transduction,
signaling pathway, Huntington
segment specification, ectoderm
disease, integrin signalling pathway,
development, mesoderm development,
T-cell activation, B-cell activation,
embryonic development, nervous system
interferon-gamma signaling
development, response to stress
pathway, oxidative stress response,
apoptosis signaling pathway,
integrin signalling pathway
Gamete generation, induction of apoptosis,
Apoptosis signaling pathway
negative regulation of apoptosis, cell cycle,
mesoderm development, hemopoiesis
Plasminogen activating cascade,
Alzheimer disease-presenilin
Protein metabolic process
pathway, plasminogen activating
cascade
Alzheimer disease-presenilin
Protein metabolic process
pathway
Alzheimer disease-presenilin
Proteolysis
pathway
Alzheimer disease-presenilin
Proteolysis
pathway, plasminogen activating
cascade
Oxidative stress response, p53
Induction of apoptosis, cell cycle, nucleobase, pathway feedback loops 2, Wnt
nucleoside, nucleotide, and nucleic acid,
signaling pathway, interleukin
metabolic process, cell cycle
signaling pathway, PDGF signaling
pathway
Metabolic process
Acetyltransferase

Biological process

Table 2: Continued.

Target gene symbol PANTHER molecular function

Mitogen-activated protein
kinase 8 (JNK)

Target names
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PLAU

PPARG

PTGS2/COX2

Urokinase-plasminogen
activator

Peroxisome
proliferator-activated receptor-γ

Prostaglandin G/H synthase 2

Oxidoreductase activity

Nuclear hormone receptor, transcription
factor, nucleic acid binding

Peptidase activity

Serine protease

PCSK9

Immune system process, signal transduction,
Blood coagulation, plasminogen
protein metabolic process, cell motion, signal
activating cascade
transduction, blood coagulation
Monosaccharide metabolism, regulation of
lipid, fatty acid, and steroid metabolism,
mRNA transcription regulation,
N/A
ligand-mediated signalling, stress response,
developmental processes, cell proliferation
and diﬀerentiation
Endothelin signaling pathway, toll
receptor signaling pathway,
Immune system process
inflammation mediated by
chemokine and cytokine signaling
pathway

N/A

FAS signaling pathway

DNA repair, protein ADP-ribosylation, stress
response

Glycosyltransferase

PARP
Proteolysis

N/A

N/A

Nuclear hormone receptor, transcription
factor, nucleic acid binding

NR3C1

N/A

Nucleobase, nucleoside, nucleotide, and
nucleic acid metabolic process

N/A

Protein binding

DNA binding, transcription factor activity

Pathway categories
T-cell activation, B-cell activation,
B-cell-mediated immunity, negative
toll receptor signaling pathway,
regulation of apoptosis, intracellular signaling
inflammation mediated by
cascade, nucleobase, nucleoside, nucleotide,
chemokine and cytokine signaling
and nucleic acid metabolic process, signal
pathway, apoptosis signaling
transduction, cellular defense response
pathway
Apoptosis signaling pathway, toll
Immune system process, intracellular protein
receptor signaling pathway,
transport apoptosis, intracellular signaling
inflammation mediated by
cascade, nucleobase, nucleoside, nucleotide,
chemokine and cytokine signaling
and nucleic acid metabolic process, signal
pathway, T-cell activation, B-cell
transduction, response to stress
activation

Biological process

NPM1

NFKBIA

NF-κB inhibitor-α

Nucleophosmin (nucleolar
phosphoprotein B23) and
telomerase
Nuclear receptor subfamily 3,
group C, member 1
(glucocorticoid receptor)
Poly(ADP-ribose) polymerase
family, member 1
Proprotein convertase
subtilisin/kexin type 9

NFKB1

Target gene symbol PANTHER molecular function

Nuclear factor NF-κB p50
subunit (NF-κB)

Target names

Table 2: Continued.
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RHOA

ROS1

Proto-oncogene
tyrosine-protein kinase ROS

ROCK1/RHO

Rho-associated protein kinase 1

Transforming protein RhoA

RAC1

Female gamete generation, immune system
process, visual perception, sensory
perception, negative regulation of apoptosis,
cell cycle, cell surface receptor linked signal
transduction, intracellular signaling cascade,
cell-cell signalling, cell-cell adhesion, protein
metabolic process, cell motion, cell cycle,
signal transduction, ectoderm development,
mesoderm development, embryonic
development, nervous system development

GTPase activity, protein binding

Kinase activity, transmembrane receptor
protein tyrosine kinase activity,
transmembrane receptor protein kinase
activity, receptor binding

Mitosis, intracellular signaling cascade, cell
adhesion, protein metabolic process, cell
motion, mitosis, signal transduction, cell
adhesion, embryonic development

Intracellular protein transport, endocytosis,
cell surface receptor linked signal
transduction, intracellular signaling cascade,
signal transduction

Biological process

Intracellular protein transport, endocytosis,
cell surface receptor linked signal
transduction, intracellular signaling cascade,
signal transduction

Kinase activity

GTPase activity, protein binding

Target gene symbol PANTHER molecular function

Ras-related C3 botulinum toxin
substrate 1

Target names

Table 2: Continued.

N/A

Pathway categories
Axon guidance mediated by
Slit/Robo, integrin signalling
pathway, inflammation mediated by
chemokine and cytokine signaling
pathway, Huntington disease, axon
guidance mediated by Slit/Robo,
FGF signaling pathway, T-cell
activation, axon guidance mediated
by netrin, EGF receptor signaling
pathway, inflammation mediated by
chemokine and cytokine signaling
pathway, cytoskeletal regulation by
Rho GTPase, aAxon guidance
mediated by semaphorins,
cytoskeletal regulation by Rho
GTPase, B-cell activation, Ras
pathway
Inflammation mediated by
chemokine and cytokine signaling
pathway, cytoskeletal regulation by
Rho GTPase
Axon guidance mediated by
Slit/Robo, angiogenesis,
heterotrimeric G-protein signaling
pathway-Gq alpha; and Go alpha
mediated pathway, axon guidance
mediated by semaphorins,
inflammation mediated by
chemokine and cytokine signaling
pathway, integrin signalling
pathway, Ras pathway, cytoskeletal
regulation by Rho GTPase, PDGF
signaling pathway
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SREBP2

TNFA

Top1

TP53

VEGFA

Wee1

Processed sterol regulatory
element-binding protein 2

Tumor necrosis factor/tumor
necrosis factor-α

Topoisomerase (DNA) I

Cellular tumor antigen p53

Vascular endothelial growth
factor A

Wee1-like protein kinase

Target names
Target gene symbol
Runt-related transcription factor
RUNX2
2
Sucrase-isomaltase
SI
(Alpha-glucosidase)

Kinase activity

Receptor binding

DNA binding, transcription factor activity

DNA topoisomerase

Tumor necrosis factor family member

DNA binding, transcription factor activity

Hydrolase activity, hydrolyzing O-glycosyl
compounds

DNA binding, transcription factor activity

PANTHER molecular function

DNA replication

Wnt signaling pathway, apoptosis
signaling pathway

Basic helix-loop-helix transcription
factor

N/A

N/A

Pathway categories

Apoptosis signaling pathway,
Huntington disease, P53 pathway
Induction of apoptosis, cell cycle, nucleobase,
feedback loops 1, p53 pathway, p53
nucleoside, nucleotide, and nucleic acid
pathway by glucose deprivation, p53
metabolic process, cell cycle
pathway feedback loops 2, Wnt
signaling pathway
Immune system process, cell cycle, cell
surface receptor linked signal transduction,
intracellular signaling cascade, cell-cell
Angiogenesis, VEGF signaling
signalling, cell cyclesignal transduction,
pathway
mesoderm development, angiogenesis,
response to stress
Mitosis, protein metabolic process
Protein kinase

Biological process
Mesoderm development, skeletal system
development, hemopoiesis
Carbohydrate metabolic process, protein
metabolic process
Nucleobase, nucleoside, nucleotide and
nucleic acid metabolic process, lipid
metabolic process
Cytokine- and chemokine-mediated signaling
pathways, ligand-mediated signalling,
immunity and defense, induction of
apoptosis
DNA replication, general mRNA
transcription activities

Table 2: Continued.
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cells, berberine also improved insulin signal transduction
through various mechanisms such as decreased phosphorylation of PERK and eLF2-α, increased phosphorylation of
IRS-1 tyrosine and AKT serine [40]. In intestinal NCI-H716
cells, berberine enhanced glucagon-like peptide 1 (GLP-1)
release and promotes proglucagon mRNA expression [41].
These results demonstrate that berberine has great potential
for insulin resistance treatment and should be explored
further in animal and human studies.
3.2. PANTHER Analysis of Berberine Targets. Distribution of
berberine therapeutic targets in vitro varied in each of these
functional classifications. Tables 3, 4, and 5 show various
distributions of the most frequent occurring berberine
targets in vitro based on molecular functions, biological
processes, and pathways, respectively.
As shown in Table 3, berberine acts on a diverse range
of molecular targets in vitro. The most common classes of
molecular functions include receptor binding, kinase activity, protein binding, transcription activity, DNA binding, and
kinase regulator activity. Known berberine targets in vitro
from the receptor binding class include epidermal growth
factor receptor (EGFR), vascular endothelial growth factor
A (VEGFA), interleukin-1β (IL1B) and interleukin-6 (IL6),
growth/diﬀerentiation factor 15 (NAG-1), and glucagon-like
peptide (GLP1).
Based on the biological process classification of in vitro
berberine targets, those targets related to signal transduction,
intracellular signalling cascade, cell surface receptor linked
signal transduction, cell motion, cell cycle control, immunity
system process, and protein metabolic process are most frequently involved (Table 4). In vitro berberine targets involved
signal transduction include cyclin-dependant kinases (CDK1
and CDK6), inhibitor of nuclear factor kappa-B kinase
subunit alpha (CHUK), epidermal growth factor receptor (EFGR), receptor tyrosine-protein kinase (ERBB2),
glucagon-like peptide (GCG), growth/diﬀerentiation factor
15 (GDF15), interferon beta (IFNB1), interleukins (IL1B,
IL2RA, and IL6), potassium voltage-gated channel subfamily
H member 2 (KCNH1), mitogen-activated protein kinases
(ERK1, ERK2, and MAPK8), nuclear factor-kappa-B p50
subunit (NFKB1), NF-kappa-B inhibitor alpha (NFKB1A),
urokinase-plasminogen activator (PLAU), Ras-related C3
botulinum toxin substrate 1 (RAC1), Rho-associated protein
kinase 4 (RHO), transforming protein RhoA (RHOA),
proto-oncogene tyrosine-protein kinase ROS (ROS1), vascular endothelial growth factor A (VEGFA).
According to the PANTHER Classification System, in
vitro berberine targets correlate with a mixture of biological
pathways, such as Alzheimer disease-presenilin and secretase pathways, angiogenesis, apoptosis signalling pathway,
FAS signalling pathway, Huntington disease, inflammation
mediated by chemokine and cytokine signalling pathways,
interleukin signalling pathway, and p53 pathways (Table 5).
The targets of berberine distributed across a large
number of PANTHER classifications of molecular functions,
biological processes, and pathways. This can be an advantage
in terms of drug discovery using berberine. Seen that
berberine targets are involved in a wide range of molecular
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Table 3: Distribution of berberine’s targets in vitro according to
molecular functions.
PANTHER molecular function
Acyltransferase activity
Anion channel activity
ATPase activity, coupled to transmembrane movement
of substances
Cation channel activity
Cation transmembrane transporter activity
Chemokine
Cyclic nucleotide-gated ion channel activity
Cysteine protease
Cytokine receptor activity
DNA binding
DNA topoisomerase
Glycosyltransferase
GTPase activity
Hydrolase activity, acting on ester bonds
Hydrolase activity, hydrolyzing O-glycosyl compounds
Kinase activator
Kinase activator activity
Kinase activity
Kinase inhibitor activity
Kinase regulator activity
Metalloprotease
Not classified
Non-receptor serine/threonine protein kinase
Nuclear hormone receptor
Nucleic acid binding
Other extracellular matrix
Other ligase
Other receptor
Other signaling molecule
Other transfer/carrier protein
Oxidoreductase activity
Oxygenase
Peptidase activity
Peptidase inhibitor activity
Phosphatase activity
Protein binding
Receptor activity
Receptor binding
Reductase
Serine protease
Structural constituent of cytoskeleton
Transmembrane transporter activity
Transcription factor
Transcription factor activity
Transmembrane receptor protein kinase activity
Transmembrane receptor protein tyrosine kinase
activity
Tumor necrosis factor family member
Voltage-gated potassium channel activity

Number
of targets
1
1
2
1
1
1
1
3
1
9
1
1
2
1
1
1
4
11
2
6
2
10
3
2
2
2
1
1
3
1
1
3
4
1
1
10
3
12
1
2
1
2
2
9
3
3
1
1

activities, in turn, can alter many pathological states of the
body. Thus, berberine can be explored for the treatment
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Table 4: Distribution of berberine’s targets in vitro according to
biological functions.
Number
PANTHER biological functions
of targets
Angiogenesis
2
Anion transport
1
Apoptosis
6
B-cell-mediated immunity
2
Blood coagulation
1
Calcium-mediated signaling
1
Carbohydrate metabolic process
7
Cation transport
1
Cell adhesion
3
Cell communication
1
Cell cycle
11
Cell cycle control
5
Cell cycle intracellular signaling cascade
1
Cell cycle signal transduction
1
Cell motility
1
Cell motion
10
Cell proliferation and diﬀerentiation
3
Cell proliferation and diﬀerentiation
1
Cell surface receptor linked signal transduction
14
Cell surface receptor-mediated signal transduction
1
Cell-cell adhesion
3
Cell-cell signaling
9
Cellular component morphogenesis
2
Cellular defense response
4
Cellular glucose homeostasis
1
Coenzyme metabolism
1
Cytokine- and chemokine-mediated signaling pathways
2
Developmental processes
1
DNA repair
1
DNA replication
2
Dorsal/ventral axis specification
1
Ectoderm development
1
Ectoderm development
8
Electron transport
3
Embryonic development
7
Endocytosis
2
Extracellular transport
2
Fatty acid biosynthesis
1
Fatty acid metabolism
1
Female gamete generation
4
Gamete generation
2
Gametogenesis
1
General mRNA transcription activities
1
Gluconeogenesis
1
Granulocyte-mediated immunity
1
Heart development
Hematopoiesis

1
1

Table 4: Continued.
PANTHER biological functions
Hemopoiesis
Immune response
Immune system process
Immune system processMitosis
Immunity and defense
Induction of apoptosis
Intracellular protein transport
Intracellular signaling cascade
Ligand-mediated signaling
Lipid metabolic process
Lipid transport
Macrophage activation
Macrophage-mediated immunity
Mesoderm development
Metabolic process
Mitosis
Monosaccharide metabolism
mRNA transcription regulation
Muscle organ development
Not classified
Natural killer cell activation
Negative regulation of apoptosis
Nervous system development
Neurological system process
NF-κB cascade
Nucleobase, nucleoside, nucleotide, and nucleic acid
metabolic process
Oncogenesis
Other intracellular protein traﬃc
Other lipid, fatty acid and steroid metabolism
Other signal transduction
Oxidative phosphorylation
Oxygen and reactive oxygen species metabolic process
Phosphatase activity cell cycle
Phosphate metabolic process
Protein ADP-ribosylation
Protein metabolic process
Protein phosphorylation
Proteolysis
Regulation of lipid, fatty acid and steroid metabolism
Response to interferon-γ
Response to stimulus
Response to stress
Response to toxin
Segment specification
Sensory perception
Signal transduction

Number
of targets
3
2
16
1
1
9
3
18
3
4
2
2
1
12
1
4
2
1
1
9
1
8
7
1
1
10
3
1
1
1
1
1
1
1
1
17
3
7
1
1
2
8
2
3
1
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Table 4: Continued.
PANTHER biological functions
Skeletal system development
Spermatogenesis
Steroid hormone metabolism
Steroid metabolism
Stress response
T-cell-mediated immunity
Transcription factor activity immune system process
Transport
Tumor suppressor
Visual perception

Number
of targets
2
2
1
2
2
2
1
1
1
1

of diﬀerent diseases. On the other hand, the nature of
multitargeting of berberine lacks in target specificity which
can become diﬃcult for drug design. Further, because
berberine can have interactions with so many molecular
structures and involve in diﬀerent pathways, much attention
must be paid to avoid interactions with other therapeutic
drugs.
3.3. Data from In Vivo Studies with a Focus on Diabetes
Mellitus. In China, Huang Lian (Rhizoma coptidis) has been
used to treat diabetes for more than 1,400 years [16].
Berberine is one of the main active alkaloids present in Rhizoma Coptidis and has shown to have good hypoglycaemic
eﬀects in vitro [37–39, 42]. Further, the chemical structure
of berberine is diﬀerent from the commonly used other
hypoglycaemic agents such as sulphonylureas, biguanides,
thiazolidinediones, or acarbose [14]. Thus, it is meaningful
to investigate the eﬃcacy and safety of berberine treatments
for diabetes mellitus to confirm the possibility of berberine
serving as a new class of antidiabetic medications. Extensive
research has been done to investigate the hypoglycaemic
eﬀects of berberine in animal models. This section will
highlight the eﬀects of berberine in diabetic animal studies,
focusing on diﬀerent mechanisms of actions of berberine.
Hyperglycemia is a hallmark metabolic abnormality
associated with metabolic diseases such as type 2 diabetes.
Berberine has shown to significantly decrease fasting blood
glucose levels in diabetic rats (diet or drug induced), this has
been observed in a number of studies [43–46]. Berberine can
reduce fasting blood glucose level via diﬀerent mechanisms.
For example, Liu et al. [43] reported that berberine reduced
fasting blood glucose (FBG) levels by inhibiting intestinal
disaccharidases in a concentration-dependent manner. Xia
et al. [46] reported berberine reduced fasting glucose level
via the inhibition of gluconeogenesis, via decreased PEPCK
and G6Pase genes in the liver, reduced hepatic steatosis, and
inhibition of FAS expression.
Current diabetes therapies do not address the key driver
of this condition, β-cell dysfunction [47, 48], and do not
alter the progressive nature of insulin secretory deficit [49].
Berberine increased pancreatic β-cell numbers and β-cell
mass in streptozotocin-induced diabetic rats [41, 50]. It also
reversed pathological changes of pancreatic β-cells in diabetic rats induced by streptozotocin and diet [51]. Further,

Table 5: Distribution of berberine’s targets in vitro according to
pathway categories.
PANTHER pathway categories
Acetyltransferase

Number
of targets
1

Alzheimer disease-amyloid secretase pathway

11

Alzheimer disease-presenilin pathway

14

Angiogenesis

11

Apoptosis signaling pathway

21

ATP synthesis

1

ATP-binding cassette (ABC) transporter

2

Axon guidance mediated by netrin

1

Axon guidance mediated by semaphorins

1

Axon guidance mediated by Slit/Robo

4

B-cell activation

7

Basic helix-loop-helix transcription factor

1

Blood coagulation

3

Cadherin signaling pathway

2

Cell cycle

4

Cytoskeletal regulation by Rho GTPase

3

DNA replication

2

EGF receptor signaling pathway

4

Endothelin signaling pathway

2

FAS signaling pathway

13

FGF signaling pathway
Heterotrimeric G-protein signaling pathway—Gq
alpha- and Go alpha-mediated pathway

4
1

Huntington disease

9

Hypoxia response via HIF activation
Inflammation mediated by chemokine and cytokine
signaling pathways
Insulin/IGF pathway-mitogen activated protein kinase
kinase/MAP kinase cascade

1
13
1

Integrin signalling pathway

6

Interferon-gamma signaling pathway

2

Interleukin signaling pathway

10

Ligand-gated ion channel

1

Membrane-bound signaling molecule

1

Pathway unclassified

19

Oxidative stress response

5

p53 pathway

12

p53 pathway by glucose deprivation

1

p53 pathway feedback loops

1

P53 pathway feedback loops 1

1

p53 pathway feedback loops 2

4

Parkinson disease

3

PDGF signaling pathway

6

Peptide hormone

1

PI3 kinase pathway

4

Plasminogen activating cascade

8
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Table 5: Continued.

PANTHER pathway categories
Protein kinase
Ras Pathway
T-cell activation
TGF-β signaling pathway
Toll receptor signaling pathway
VEGF signaling pathway
Vitamin D metabolism and pathway
Wnt signaling pathway

Number
of targets
1
5
7
4
9
7
1
4

in berberine treated diabetic rats, the pancreatic and plasma
insulin levels increased after glucose load, reducing blood
glucose levels [41, 50]. These observations are significant
as berberine may be explored further as an additional
therapy to existing antidiabetic drugs to eﬀectively preserve
β-cell functions, reverse β-cell damage, and promote insulin
secretion in diabetes patients.
Further to β-cell dysfunction and insulin secretory deficit
in diabetes, defects in insulin receptor (InsR) expression or
function can cause insulin resistance and diabetes mellitus
[52]. Thus, regulation of InsR expression may improve
insulin resistance in diabetes mellitus. Berberine increases
InsR mRNA and protein expression in human liver cells and
in animal model in a dose- and time-dependent manner
[38]. Berberine upregulates InsR and leads to enhanced
insulin signalling pathway, confirming berberine as an
insulin sensitiser.
Glucagon-like peptide 1 (GLP-1) is an intestinal peptide
hormone released in response to food ingestion [53]. GLP1 enhances meal-related insulin secretion and promotes
glucose tolerance. In streptozotocin-induced rats, berberine
enhanced GLP-1 release and promotes proglucagon mRNA
expression, increased beta cell mass and pancreas insulin
levels after glucose load [41]. This observation was in line
with the groups, previous experiments in vitro. Lu et al. [50]
also reported that berberine increased proglucagon mRNA
expression and plasma insulin levels in streptozotocininduced diabetic rats. The glucagon gene encodes GLP-1 and
the increased expression of proglucagon mRNA assists in
controlling the blood glucose homeostasis.
Berberine also reduced body weight and caused a significant improvement in glucose tolerance without altering
food intake in db/db mice [54]. Oral glucose tolerance
improvement in diabetic rats after berberine treatment has
also been observed in other studies [55, 56].
Long-term hyperglycaemia can lead to increased risk of
cardiovascular complications. In hyperglycemia and hypercholesterolemia rats with injured cardiac functions, berberine
(15, 30 mg/kg/day, i.g for 6 weeks) increased cardiac output,
left ventricular systolic pressure, and +d p/dtmax by 64,
16, and 79%, but decreased left ventricular end diastolic
pressure and −d p/dtmax by 121 and 61% in the rats
receiving HSFD/streptozotocin, respectively, when compared
with the untreated rats of hyperglycemia and hypercholesterolemia [57]. Berberine caused significant increase

in cardiac fatty acid transport protein-1 (159%), fatty
acid transport proteins (56%), fatty acid beta-oxidase
(52%), and glucose transporter-4. These results demonstrate the cardioprotective functions of berberine in hyperglycemia/hypercholesterolemia through alleviating cardiac
lipid accumulation and promoting glucose transport 4 [57].
Another study also showed improved vasorelaxation in
impaired aorta in diabetic rats after berberine treatment
(100 mg/kg/day, 8 weeks) [45]. Thus, in addition to its
hypoglycaemic eﬀects, berberine can also be investigated for
cardiomyopathy in diabetes.
Berberine also regulates lipid metabolism which is
closely related to diabetes. In rats with induced diabetic
hyperlipidemia, berberine (75, 150, 300 mg/kg/day for 16
weeks) eﬀectively reduced liver weight and liver/body weight
ratio, levels of total cholesterol, triglycerides, and lowdensity lipoprotein-cholesterol [58]. In rats with a high fat
diet, berberine significantly reduced body weight, alleviated
liver steatosis, and improved insulin resistance [59]. This
observation indicates that berberine can be an eﬀective
treatment for diabetes with obesity.
Clinically, preeminent factors for monitoring glycaemia
and evaluating the risks of complications of diabetes include
FBG, haemoglobin A1c (HbA1c ) [60]. Triglyceride synthesis
is closely associated with glucose metabolism so serum
triglyceride levels are determined. Clinical studies often
measure FBG, HbA1c , and triglyceride levels, along with
other factors to study the hypoglycaemic eﬀects of berberine.
The eﬃcacies of berberine in type 2 diabetes patients
have been reported. Through literature search, key clinical
studies on berberine eﬀects on type 2 diabetes patients are
summarised.
Zhang et al. [61] conducted a randomized, double-blind,
placebo-controlled multicenter trial (n = 116). The authors
found that when berberine (1.0 g daily) was administered
for 3 months in type 2 diabetes patients with dyslipidemia,
the fasting and postload plasma glucose levels decreased
from 7.0 ± 0.8 to 5.6 ± 0.9 and from 12.0 ± 2.7 to 8.9 ±
2.8 mM/L, HbA1c from 7.5 ± 1.0% to 6.6 ± 0.7%. Further,
in the treatment group, triglyceride levels were reduced
from 2.51 ± 2.04 to 1.61 ± 1.0 mM/L, total cholesterol from
5.31 ± 0.98 to 4.35 ± 0.96 mM/L, and LDL-cholesterol from
3.23 ± 0.81 to 2.55 ± 0.77 mM/L. Results from the treatment
group was significant compared to the control group. In the
treatment group, patient’s body weight was also significantly
reduced. Mild-to-moderate constipation was reported in 5
patients from the treatment group and 1 patient from the
control group; however, this finding was not statistically
significant. No other adverse events were reported. At 3
months, berberine was found to be eﬀective in lowering
blood glucose, lipids, body weight, and blood pressure with
a good safety profile.
Yin et al. reported a 3-month study comparing berberine
to antidiabetic drug metformin (0.5 g t.i.d) [14]. In this
study, berberine exhibited identical eﬀect as metformin in
the regulation of glucose metabolism, significant decreases
in HbA1c (by 2%, P < 0.01), FBG (by 3.8 mmol/L; P < 0.01),
and postprandial blood glucose (PBG) (by 8.8 mmol/L;
P < 0.01). Further, the regulation of lipid metabolism was
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better in the berberine group than the metformin group.
Triglycerides and total cholesterol levels were significantly
lower than in the metformin group (P < 0.05). At the
same time, the same group of researchers used berberine
as a combination therapy to evaluate its additive or synergistic eﬀects on the commonly used hypoglycemic agents,
such as sulphonylureas, biguanides, thiazolidinediones, and
acarbose. Patients were given 500 mg berberine three times
daily for 3 months in addition to their previous treatment.
At week 5, berberine significantly (P < 0.01) reduced HbA1c
(from 8.1% to 7.3%), FBG, PBG, and fasting insulin levels.
Blood lipids including triglyceride, total cholesterol, and
LDL-C decreased significantly lowered compared to baseline.
In both studies, incidences of gastrointestinal adverse events
were observed, including diarrhea, constipation, flatulence,
and abdominal pain. Interestingly, patients did not suﬀer
from severe gastrointestinal adverse events when berberine was used alone and in combination therapy; adverse
eﬀects disappeared after berberine dosage was reduced. No
pronounced elevation in liver enzymes or creatinine was
observed, suggesting that berberine did not cause damage to
the liver or kidneys.
Another clinical study [62] randomly divided 97 type 2
diabetes mellitus patients into berberine treatment (1 g/day)
for 2 months, using metformin therapy (1.5 g/day) and
rosiglitazone group (4 mg/b.i.d) as reference groups. Blood
samples were taking before and after treatments to measure
FBG, HbA1c , triglyceride, and serum insulin levels. Compared to values prior to treatment, berberine significantly
lowered FBG by 25.9% (P < 0.001), HbA1c by 18.1%
(P < 0.00), and triglycerides by 17.6% (P < 0.01). The
hypoglycaemic eﬀects of berberine were comparable to metformin and rosiglitazone. Serum insulin level was declined
significantly (P < 0.01) by 28.2%; this indicates increased
insulin sensitivity in peripheral tissues by berberine treatment. Peripheral blood lymphocytes from berberine treated
patients were isolated to examine the InsR expression. The
surface expression of InsR significantly elevated by 3.6-fold
after berberine treatment.
Metformin and rosiglitazone are not recommended for
use in diabetic patients with liver function damage [54, 63].
So the eﬀect of berberine was tested in hyperglycaemic
patients with hepatitis. Hepatitis B and C patients with
hyperglycaemia received berberine at 1 g/day for 2 months.
In both diabetic hepatitis B and C patients, berberine
significantly reduced FBG and triglyceride levels. Berberine
treatment also reduced the elevated alanine transaminase
and aspartate aminotransferase levels in these patients. Overall, berberine is safe and eﬀective in hyperglycaemic patients
with liver function damage.
Table 6 compares clinical studies of berberine in diabetes
patients. Across the studies, berberine has shown to significantly reduce FBG, PBG, and HbA1c levels. Berberine also
demonstrated ability to reduce triglyceride and cholesterol
levels. Minimal gastrointestinal side eﬀects were shown but
no liver or kidney damage was observed. These observations
in diabetes patients demonstrate that berberine is a safe and
eﬀective antidiabetic agent.
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4. Discussion
The “rule-of-five” analysis by Lipinski et al. [7] shows that
poor absorption or permeation of a compound is more likely
when there are more than five hydrogen-bond donors; the
molecular mass is more than 500 Da; the lipophilicity is high
(expressed as cLog P > 5); the sum of nitrogen and oxygen
is more than 10. Specific structural and physiochemical
properties, such as “rule-of-five,” are required for clinical
drugs to have suﬃcient levels of eﬃcacy, bioavailability, and
safety, which define target sites to which drug-like molecules
can bind [4].
Plant compounds exhibit enormous structural diversity
and only a small portion of the diversity has been explored
for its pharmacological potential [64]. In recent years, herbal
compounds have been source of new drugs [64]. Approximately 28% of new molecular entities (NMEs) between
1981 and 2002 were natural products or natural product
derived; further to this, 20% of these NMEs were natural
product mimics [65]. There are a number of successful plantderived drugs, especially in anti-cancer treatment. Medicinal
herbal compounds have become an important source for
the discovery of new drugs. Further, drugs derived from
medicinal plants can also be used as drug leads suitable for
optimization by medicinal and synthetic chemists [65].
As Chinese herbal medicine becomes increasingly popular in the west, researchers are spending more time looking
into mechanisms of actions of crude extracts and herbal
compounds such as berberine. In recent years, extensive
research has been done to explore the eﬀects of berberine on
various cell lines in vitro. In cell-based studies, berberine has
shown eﬀects on multiple molecular targets and alters various biological pathways. Berberine associates with a range of
conditions, particularly diabetes, hyperlipidemia, and cancer.
Many in vitro studies showed potent anticancer properties
of berberine against various cancer cells. This observation
is valuable in the search for new anti-cancer therapeutics
with potent anti-cancer eﬀects but reduced side eﬀect. So
berberine may potentially be developed into an anticancer
agent, like other natural compounds (taxol, camptothecin)
that have been developed and used as anticancer agents.
Diabetes mellitus is a major health problem around the
world and its prevalence is on the rise. Diabetes mellitus drug
therapy is limited by availability of eﬀective medications, as
existing oral hypoglycaemic agents often have side eﬀects
and fails in long-term administration [14]. Berberine has
shown significant results in fasting blood glucose levels
reduction, increase in insulin sensitivity, and improvement
in insulin resistance in vitro, in diabetic animal models and
in diabetic patients. Further, berberine shows mechanism
that current antidiabetic drugs do not have. For instance,
berberine has shown eﬀects on pancreatic β-cell number and
mass improvement [41, 50, 51]. In addition, berberine has
a good safety profile and does not show side eﬀects such
as hypoglycaemia, weight gain, or liver and kidney damage.
Metformin and rosiglitazone are not recommended for use
in diabetic patients with liver function damage [54, 63].
Berberine has shown to be eﬀective in the reduction of
blood glucose level and is safe in diabetic patients with
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Table 6: Comparison of clinical studies of berberine in diabetes patients.

Study type

Randomised,
double-blind,
placebo-controlled,
multiple-center

Study subjects

Berberine dosage Control treatment Major findings

Type 2 diabetes
0.5 g, b.i.d for 3
and
months
dyslipidemia
(n = 116)

Type 2 diabetes 0.5 g, t.i.d for 3
months
(n = 36)
Randomised, blinded,
placebo-controlled

Type 2 diabetes
0.5 g, t.i.d for 3
poorly
months
controlled
(n = 48)

Type 2 diabetes 1 g/day for 2
(n = 97)
months

Placebo

Metformin (0.5 g
t.i.d)

Existing
anti-diabetic
treatment

Metformin
(1.5 g/day);
rosiglitazone
(4 mg/day)

Significantly reduced
FBG, HbA1c , and
triglycerides
Serum insulin level was
declined significantly
(P < 0.01), increased
insulin sensitivity in
peripheral tissues.
Significantly elevated
surface expression of
InsR by 3.6-fold

N/A

Side eﬀects

Mild to moderate
constipation in 5
patients

Reference

[61]

Significantly reduced
FBG, PBG, and HbA1c
Significantly reduced
plasma triglycerides
Lowered FBG and PBG
Significantly decreased
HbA1c
Significantly reduced
fasting plasma insulin
and HOMA-IR

Randomised

Type 2 diabetes
with chronic
1 g/day for 2
hepatitis C virus
months
infection
(n = 35)

Significantly reduced
fasting and postload
plasma glucose, HbA1c
Significantly reduced
triglyceride, total
cholesterol, and
LDL-cholesterol

Transient
gastrointestinal
adverse eﬀects. No
liver or kidney
damage

No adverse events

[14]

[62]

Significantly reduced
FBG and triglyceride
levels
Reduced the elevated
ALT and aspartate
aminotransferase levels

b.i.d: twice daily; t.i.d: three times daily; FBG: fasting blood glucose; HOMA-IR: homeostasis model of assessment—insulin resistance; PBG: postprandial
blood glucose.

viral hepatitis [62]. Berberine can therefore be investigated
as an eﬀective diabetes therapy with patients with liver
function damage. In addition to its hypoglycemic eﬀects
in diabetic patients, berberine also reduced triglyceride and
cholesterol levels. Abnormalities in lipid metabolism often
deteriorate diabetes and cause complications. The regulation
of lipid metabolism in diabetes patients by berberine may
have clinical significance in managing diabetic patients with
hyperlipidemia. Although there are only a small number of
clinical studies and evidence is limited, current reports still
show a promising future for berberine being developed into
a new antidiabetic agent.
In China, berberine has been manufactured into the
over-the-counter drug Huang Lian Su Pian, also known
as Coptis Extract Tablets for the treatment of traveler’s
diarrhea [14, 17]. However, in vitro and in vivo studies have

shown that berberine has potent anti-cancer, antidiabetic,
antilipidemic, and anti-inflammatory eﬀects. Therefore, further clinical studies are warranted to investigate the potential
of berberine in the application of cancer and diabetes
treatments in the future.
Pharmacological activity of CHMs begins with the
binding of the active components to their molecular targets.
CHMs are considered as typical multitherapeutics that can
interact simultaneously with multiple targets. The origins
and the progression of diseases are multifactorial. Complex
disorders such as cancer, cardiovascular disease, and depression tend to result from multiple molecular abnormalities,
not from a single defect [66]. Biochemical and genetic studies
revealed the molecular mechanism that underlie common illnesses [66]. Reports show that targets for neoplasm diseases,
circulatory system diseases, infectious diseases, and nervous
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system and sense organs disorders constitute the largest
number of targets [1]. Because drug targets are presented at
the molecular level, increased knowledge of herbal targets
can facilitate deeper understanding of complex diseases at
its fundamental level. In turn, it is likely to determine the
optimal molecular targets for therapeutic intervention [6].
Further to assisting the molecular dissection of the mechanism of action of CHMs, knowledge on herbal targets makes
it possible to use disease specific targets and design more
desirable herbal drugs/formulas with increased specificity
and eﬃcacy. Target-oriented synthesis in drug discovery
involves in preselected protein targets [67]. Binding of
drugs to preselected protein target/s is dependent on which
biological pathway the drug is aimed to modulate the target
or the diseased pathway(s) [67]. Target and disease specific
drug design results in improved eﬃcacy and reduced side
eﬀects, especially in high impact diseases that require more
eﬀective and more treatment options. However, due to
the fact that diseases often involve in multiple molecular
abnormalities, diversity-oriented syntheses are used in eﬀorts
to identify simultaneously therapeutic protein targets and
their small-molecule regulators [67]. Target-oriented drug
design allows more focused drug design, which in turn costs
less time and money for pharmaceutical companies.
Protein structure of well-validated old and new targets
should be able to guide the chemical eﬀort directed at
new drugs [68]. Study of various aspects of known targets
including molecular mechanism of their binding agents and
related adverse eﬀects is useful for finding clues to new target
identification [9]. Based on the knowledge of molecular
targets and molecular understanding of disease state and
using this knowledge will allow some direction in identifying
potential targets. Potential herbal targets may come from
the same class as confirmed therapeutic targets and have
similar physiological functions, or maybe a structure along
a biological pathway. Additionally, with increased number of
potential targets from ∼500 to >5,000, the nature of pharmaceutical research has changed. This increase in numbers has
given researchers more opportunities to discover and design
new and improved drugs.
Target selection may be one of the most important
determinants of attrition and the overall R&D productivity.
There are few ways to overcome this challenge and improve
the target selection process, in turn, improving R&D productivity. First of all, researchers can discover new target
classes. Targets of herbal medicine are becoming a popular
resource to find new target classes. In addition, increased
understanding of genetic variations/polymorphisms of drug
targets or drug metabolising enzymes can assist in target
selection and drug metabolism. Further, the use of new
technology can help to speed up the early exploratory
discovery phase of drug discovery.
In summary, updated knowledge of herbal targets is
valuable contribution to complex disease understanding and
clinical responses. Further, drug discovery and development
from herbal medicines can be supported by new target
discovery and target-focused drug design. This will speed
up the exploratory phase of drug R&D and benefit the
pharmaceutical industry in terms of cost and time.

27

Abbreviations
Bax:
FBG:
GLP-1:
HbA1c :
InsR:
PBG:

BCL2-associated X protein
Fasting blood glucose
Glucagon like peptide 1
Hemoglobin A1c
Insulin receptor
Postprandial blood glucose.

Authors’ Contribution
Xiao-Wu Chen and Yuan Ming Di contributed equally to this
work.

References
[1] C. J. Zheng, L. Y. Han, C. W. Yap, B. Xie, and Y. Z. Chen,
“Trends in exploration of therapeutic targets,” Drug News and
Perspectives, vol. 18, no. 2, pp. 109–127, 2005.
[2] B. Bryant and K. Knights, Pharmacology for Health Professionals, Mosby Elsevier, Chatswood, Australia, 3rd edition, 2011.
[3] A. L. Hopkins and C. R. Groom, “The druggable genome,”
Nature Reviews Drug Discovery, vol. 1, no. 9, pp. 727–730,
2002.
[4] C. J. Zheng, L. Y. Han, C. W. Yap, Z. L. Ji, Z. W. Cao, and Y.
Z. Chen, “Therapeutic targets: progress of their exploration
and investigation of their characteristics,” Pharmacological
Reviews, vol. 58, no. 2, pp. 259–279, 2006.
[5] J. Drews, “Genomic sciences and the medicine of tomorrow,”
Nature Biotechnology, vol. 14, no. 11, pp. 1516–1518, 1996.
[6] J. Drews and S. Ryser, “The role of innovation in drug development,” Nature Biotechnology, vol. 15, no. 13, pp. 1318–
1319, 1997.
[7] C. A. Lipinski, F. Lombardo, B. W. Dominy, and P. J. Feeney,
“Experimental and computational approaches to estimate
solubility and permeability in drug discovery and development settings,” Advanced Drug Delivery Reviews, vol. 46, no.
1–3, pp. 3–26, 2001.
[8] X. Chen, C. J. Zheng, L. Y. Han, B. Xie, and Y. Z. Chen,
“Trends in the exploration of therapeutic targets for the
treatment of endocrine, metabolic and immune disorders,”
Endocrine, Metabolic and Immune Disorders, vol. 7, no. 3, pp.
225–231, 2007.
[9] X. Chen, Z. L. Ji, and Y. Z. Chen, “TTD: therapeutic target
database,” Nucleic Acids Research, vol. 30, no. 1, pp. 412–415,
2002.
[10] J. Qiu, “Traditional medicine: a culture in the balance,”
Nature, vol. 448, no. 7150, pp. 126–128, 2007.
[11] R. Stone, “Biochemistry: lifting the veil on traditional Chinese medicine,” Science, vol. 319, no. 5864, pp. 709–710,
2008.
[12] P. Barnes, E. Powell-Griner, K. McFann, and R. Nahin, “Complementary and alternative medicine use among adults:
United States, 2002,” Advanced Data From Vital and
Health Statistics 343, National Center for Health Statistics,
Hyattsville, Md, USA.
[13] E. Ernst and M. H. Pittler, “Herbal medicine,” Medical Clinics
of North America, vol. 86, no. 1, pp. 149–161, 2002.
[14] J. Yin, H. Xing, and J. Ye, “Eﬃcacy of berberine in patients
with type 2 diabetes mellitus,” Metabolism: Clinical and
Experimental, vol. 57, no. 5, pp. 712–717, 2008.
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